Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-6 of 6 for your search:
Drug:
larotaxel
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TCD6511
, EudraCT:2006-006474-21, NCT00327743
2.
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EFC6088
, XRP9881B/2001, EUDRACT : 2004-000572-14, NCT00087958
3.
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TCD6595
, XRP9881, NCT00386685
4.
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TCD10037
, XRP9881, NCT00387907
5.
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-Cyclophosphamide in Breast Cancer Patients
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 to 75
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EFC10073
, EudraCT 2006-006473-24, NCT00485979
6.
Phase I Study of RPR 109881A (a Taxoid Derivative) Administered as a Weekly 1-Hour Intravenous Infusion for Advanced Solid Tumors (Summary Last Modified 07/98)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Protocol IDs:
CAN-NCIC-IND101
, NCI-V96-1096, IND101
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute